The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Patient-derived organoids can be established from uveal melanoma tumors. Credit: Investigative Ophthalmology & Visual Science (2024). DOI: 10.1167/iovs.65.13.60 ...

3D models provide a realistic environment for studying uveal melanoma They enable effective drug testing and personalized treatment approaches This research could lead to innovative therapies and ...

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in ...

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

We expect investors to focus on the sales performance of Immunocore Holdings plc’s IMCR sole marketed drug, Kimmtrak ...

A benefit for South Lake Tahoe local Jennifer Milligin, who is recovering from Ocular Melanoma (eye cancer), will be held at ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these ...